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Summary 
Tumor necrosis factor (TNF)  is a pleiotropic mediator of inflammation that has been impli- 
cated in the pathogenesis of  devastating clinical syndromes including septic shock. We have inves- 
tigated the role of a TNF-responsive phosphatidylcholine-specific phospholipase C  (PC-PLC) 
for the cytotoxic and proinflammatory activity of TNF. We show here that the cytotoxicity 
signaled for by the so-called "death domain" of the p55 TNF receptor is associated with the 
activation of PC-PLC.  The xanthogenate tricyclodecan-9-yl (D609),  a specific and selective 
inhibitor of PC-PLC, blocked the cytotoxic action of TNF on L929 and Wehi164  cells.  In 
vivo, D609 prevented both adhesion molecule expression in the pulmonary vasculature and the 
accompanying leukocyte infiltration in  TNF-treated  mice.  More  strikingly,  D609  protects 
BALB/c mice from lethal shock induced either by TNF, lipopolysaccharide, or staphylococcal 
enterotoxin B. Together these findings imply PC-PLC as an important mediator of the patho- 
genic action of TNF, suggesting that PC-PLC may serve as a novel target for anti-inflamma- 
tory TNF antagonists. 
T  NF,  originally defined by its  antitumoral  activity,  is 
now recognized as  a potent polypeptide mediator of 
inflammation and cellular immune response, that has been 
implicated in the pathogenesis of several clinical syndromes 
(1).  Furthermore,  TNF has  been demonstrated to induce 
cell death in several tumor cell lines (2). TNF elicits its ex- 
trenfly wide variety of biological effects through two dis- 
tinct cell surface receptors of 55-  (TNF-R55)  and 75-kD 
(TNF-R75)  apparent  molecular  mass,  respectively,  that 
transmit signals to the cytoplasm and the nucleus (3). Both 
proinflammatory and cytotoxic activities have been mainly 
ascribed  to  signaling  events  coupled to  TNF-R55  (3-7). 
Recently, it was shown that binding of TNF to TNF-R55 
mediates the activation of at least two independent signal- 
ing pathways,  one initiated by a neutral sphingomyelinase 
(N-SMase) 1 which results in subsequent activation ofa cerarn- 
~  Abbreviations used in this paper: A-SMase, acid sphingomyelinase; DAG, 
diacylglycerol; D609, tricyclodecan-9yl-xanthogenate;  GAIN, D-galac- 
tosamine; hTNF, human TNF; mTNF, murine TNF; NF-KB, nuclear 
factor KB; PC-PLC, phosphatidylcholine-specific  phospholipase C; PKC, 
protein kinase C; PLA2, phospholipase A2; SEB, staphylococcus  entero- 
toxin B; SMase, sphingomyelinase;  VCAM-I, vascular  cell adhesion mol- 
ecule 1; WT, wild type. 
ide-activated protein kinase,  Raf-1  kinase,  and eventually 
phospholipase  A 2  (PLA2) (8-10).  The  other pathway in- 
volves activation of phosphatidylcholine-specific phospho- 
lipase  C  (PC-PLC), which results  in breakdown of PC in 
phosphorylcholine and the lipid messenger molecule dia- 
cylglycerol (DAG). TNF-induced DAG generation through 
PC-PLC appears instrumental in the regulation of protein 
kinase C  (PKC)  and an acid sphingomyelinase (A-SMase) 
(i 1,  12).  Notably, the activation of PC-PLC has been also 
implicated in  the  signaling  of other proinflammatory cy- 
tokines such as IL-1 and IFN-y (for a review see reference 
13).  Through the  generation  of ceramide, A-SMase pro- 
vides an important cofactor for the activation of the tran- 
scription  factor nuclear  factor  (NF)-KB  (12).  NF-KB  in 
turn seems to play an important role in the control of ex- 
pression of several inflammatory proteins, such as IL-1 and 
IL-6 (14). However, despite recent progress in understand- 
ing signaling pathways of TNF-R55, the molecular mecha- 
nisms  of TNF-mediated cytotoxicity and proinflammatory 
activity remain elusive. PLA  2 has been mostly incriminated 
to mediate TNF cytotoxicity (15,  16), however, the mech- 
anisms  of PLA2-induced  cytotoxicity remained  obscure. 
Strikingly, TNF cytotoxicity can be shown in the absence 
of PLA  2 activity (2). Thus, pathways other than PLA2 must 
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identified cytoplasmic region of the TNF-R55, designated 
"death domain," seems to play a major role in TNF cyto- 
toxicity (5,  17).  We have previously shown by structure- 
function analysis of TNF-R55 that activation of PC-PLC 
rather  than  PLA2  is  triggered  by  the  death  domain  (8), 
which prompted us to investigate the possible involvement 
of PC-PLC in TNF-mediated cytotoxicity and proinflam- 
matory activity of TNF. 
In the present study we employed the tricyclodecan-9yl- 
xanthogenate (D609), which has been identified as a potent 
and specific inhibitor of PC-PLC (12,  18,  19).  In particu- 
lar,  D609 has no inhibitory effects on TNF-mediated acti- 
vation of PLA2, neutral SMase, or proline-directed protein 
kinase (8, 12). Furthermore, it has been reported that D609 
does not inhibit PKC, phosphoinositol-specific phospholi- 
pase C~/(PI-PLC3~), tyrosine kinases, or phosphatases (12, 20). 
Here we show that inhibition of PC-PLC by D609 blocks 
the cytotoxic and proinflammatory action of TNF both in 
vitro and in vivo. Furthermore, we show that D609 treat- 
ment protects mice  from lethal  shock  induced  either by 
TNF, LPS, or staphylococcus enterotoxin B  (SEB).  These 
results  provide evidence for an important role of PC-PLC 
Figure 1.  The death domain of TNF-R55 signals for both cytotoxicity 
and PC-PLC activation in 70Z/3  cells.  (.4) Schematic representation of 
cytoplasmic domains ofWT TNF-R55 and TNF-R55A345. (B) Activa- 
tion of PLA2 in 70Z/3 transfectants. Cells were left untreated or treated 
with hTNF for 15 rain, Resuhs of enzymatic assays are expressed as per- 
cent  increase  over  untreated  controls.  The  values  represent  the  mean 
(+SD)  of three independent experiments. (C) Activation of PC-PLC in 
70Z/3 transfectants. Cells were left untreated or treated for 2 rain with ei- 
ther mTNF or hTNF  as indicated.  P,.esuhs are expressed as percent in- 
crease over untreated controls. Basal DAG production of untreated cells 
corresponded to 40 pmol of DAG per 106 70Z/3 cells.  The values repre- 
sent the mean (+SD) of three independent experiments. (D) TNF-medi- 
ated cytotoxicity is triggered by the death domain of TNF-R55.  Cyto- 
toxicity assays with 70Z/3 (V1, C)) or 70Z/3 WT TNF-R.55 cells  (.)  or 
70Z/3 TNF-P,.55A345  cells  (S)  were  performed in quadruplicates  (SD 
<5%). Cells were left untreated or treated for 18 h with hTNF ([:3, U, O) 
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Figure 2.  D609 blocks TNF-mediated cytotoxicity. (A) D609 inhibits 
TNF-mediated  cytotoxicity  in  actinomycin  D~sensitized  L929  and 
Wehi164 cells. Murine fibrosarcoma L929 or Wehi164 cells were left un- 
treated (U]) or pretreated for  1 h  with 50/.Lg/ml (I),  25 /.Lg/mJ (￿9  or 
12.5 ~g/ml D609  (0) in the presence of I  ~g/ml actinomycin D. Cells 
were treated in quadruplicates (SD <5%)  with mTNF for 18 h  (n =  5). 
(B)  D609  inhibits TNF-mediated cytotoxicity in Wehi164 cells. Wehi164 
cells were left untreated ([]) or pretreated for 1 h with 50 b~g/ml (I),  25 
btg/rnl (C)), or 12.5 Ixg/ml D609 (O). Cells were incubated in quadrupli- 
cates (SD <5%) with mTNF for 18 h  (n =  5). 
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Materials and Methods 
Cell Culture  and Reagents.  The mouse pre-B  cell line 70Z/3, 
and  the  mouse fibrosarcoma  cell lines L929  and Wehi164  were 
originally obtained from the American Type  Culture  Collection 
(ATCC; Rockville, MD).  Cells were maintained in a mixture of 
Click's  (50%  vol/vol)  and  RPMI  (50%  vol/vol)  supplemented 
with 10% fetal calf serum,  10 mM glutamine, and 50 p~g/ml each 
of streptomycin and penicillin in a humidified incubator contain- 
ing 5% CO2. 
Highly purified recombinant human  TNFcr  (hTNF,  3  ￿  107 
U/rag  protein)  and  routine  TNF~x  (mTNF,  1.2  ￿  107) were 
kindly provided by Dr. G. Adolf (Boehringer Research Institute, 
Vienna,  Austria).  D609  was  provided  by  Drs.  Sauer  and  Amt- 
mann  (German  Cancer  Center,  Heidelberg,  Germany)  or pur- 
chased from Biomol (Hamburg,  Germany). 
The  exotoxin  SEB,  the  endotoxin  LPS,  and  actinomycin  D 
were purchased  fi:om Sigma (Munich,  Germany).  D-galactosamine 
(GAIN) was obtained from tkoth (Kadsruhe,  Germany). 
Mice.  BALB/c and C57BL/6 mice were purchased from the 
Zentralinstitut fl.ir Versuchstierzucht (Hannover, Germany). 
Expression of TNF-R55 Deletion Mutants in 70Z/3  Cells.  The 
generation of stable 70Z/3 transfectants expressing either the hu- 
man  wild-type  (WT)  TNF-P,.55  or the  deletion  mutant  TNF- 
R55A345 has been described elsewhere (4,  8). The 70Z/3 trans- 
fectants displayed 1,060 TNF-R55/cell and 1,260 TNF-RA345/ 
cell with affinities of 2.2  X  10 -l~ M  and 4.5  ￿  10 -l~ M, respec- 
tively (4,  8). 
Assays for PC-PLC and PLA  2.  To measure PLA  2 activity, cells 
were labeled  for 48  h  with  [N-methyl-lgC]chohne  (Amersham, 
Braunschweig,  Germany;  1  p,  Ci/ml, specfic activity, 56.4  mCi/ 
nunol).  One  million  cells  in  duplicates  were  left  untreated  or 
Figure 3.  Ceramide-induced death of Wehil64 cells is not affected by 
D609  treatment.  Wehi164 cells were left untreated  (black bars) or pre- 
treated for 1 h with 50 p,g/ml (grey bars) or 25 ttg/ml D609 (white  bars) in 
the presence  of 1 ~g/ml actinomycin  D. Cells were treated  in triplicates 
with Cs-ceramide for 8 h. The values represent the mean (•  of three 
independent experiments. 
Figure 4.  D609 selectively inhibits  TNF-induced PC-PLC activation 
in Wehi164 cells. (A) D609  inhibits  TNF-induced PC-PLC activation. 
Cells were left untreated  (0) or preincubated  with 100 p,g/nal D609 for 
60 rain (O). Cells were stimulated with 100 ng/ml mTNF, and PC-PLC 
activity was estimated from 1,2-DAG production.  Results  are expressed 
as percent increase over untreated  controls. Basal DAG production of un- 
treated cells corresponded  to 61.5 pmol of DAG per 106 cells. The values 
represent  the mean (-+SD) of three independent experiments.  (B) D609 
inhibits  TNF-induced activation  of PC-PLC.  Cells were left untreated 
(solid bar) or pretreated  for 60 min with various concentrations  of D609 
(hatched bars) followed by stimulation  with 100 ng/ml mTNF for 2 rain. 
Results (•  of three independent experiments  are expressed as percent 
increase  of TNF-induced  DAG  production  compared  with  untreated 
controls.  (C)  TNF-induced PLA  2 activation  is not inhibited by D609. 
Cells were left untreated  (0) or preincubated  with 100 p,g/ml D609 for 
60 min (￿9  followed by stimulation with 100 ng/ml mTNF for indicated 
times. Results  (•  of three  independent experiments  are expressed as 
percent  increase  of TNF-induced  lysophosphatidylcholine  production 
compared with untreated  controls. 
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phorylcholine was analyzed by combined TLC and two-dimen- 
sional laser densitometry as described (11).  For PC-PLC  assays, 
serum-starved cells were labeled with L-lyso-3-PC-l-p4C]palmi  - 
toyl (Amersham). Cells were left untreated or treated with either 
hTNF or mTNF for 2 min. TNF-induced changes of DAG levels 
were  estimated by  TLC  analysis  of neutral  lipids followed by 
two-dimensional scanning as recently described (11). 
Cytotoxicity Assay.  Cytotoxicity assays with 70Z/3 or 70Z/3 
WT  TNF-R.55  cells  or 70Z/3  TNF-R55A345  cells were per- 
formed in quadruplicates in microtiter plates at a densi  W of 2  ￿ 
104 cells/well. Cells were left untreated or treated for 18 h with 
graded concentrations of hTNF or mTNF. MTT  (1-[4,5-dime- 
thylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)  was  added 
and after solubilization of MTT-formazan  (1-[4,5-dimethylthia- 
zol-2-yl]-3,5-diphenylformazan) crystals  with  HCl-isopropanol, 
the OD was determined at 570 nm. The percent cytotoxicity was 
calculated from the formula 100 (a-b)/a where a and b represent 
the ODs70 values of untreated and treated samples, respectively. 
Cytotoxicity assays with  L929  or Wehi  164  cells  were  per- 
formed as previously described (18,  19). Briefly, murine fibrosar- 
coma L929 or Wehi 164 cells at a density of 5 X  104 or 2  ￿  104 
cells/well, respectively, were left untreated or pretreated for 1 h 
with  D609  in  the  presence  of 1  Izg/ml actinomycin D.  Cells 
were treated in quadruplicates with mTNF for 18 h and cytotox- 
icity was  determined by crystal violet staining or specific ~lCr- 
release as described (21, 22). 
Immunohistochemistry.  For determination of vascular cell ad- 
hesion molecule  1 VCAM-1  expression, cryostat sections from 
frozen lung tissue were prepared and analyzed by an indirect im- 
munoperoxidase technique (23).  Frozen sections were incubated 
with  mAb  specific  for  either  murine  VCAM-1  (M/K-2.7, 
ATCC)  or the murine Mac-I antigen expressed on monocytes, 
granulocytes, and NK cells (M1/70,  ATCC). The sections were 
developed  using  a  peroxidase-coupled  affinity-purified  rabbit 
anti-rat  Ig  (Dianova,  Hamburg,  Germany)  and  counterstained 
with hematoxylin. 
Results and Discussion 
TNF-R55  Death  Domain  Signals Activation  of PC-PLC. 
TNF has been shown to trigger cell death through a COOH- 
terminally located domain of TNF-R55,  called "death do- 
main,"  which  is  also  responsible for  the  activation of the 
signal transduction enzyme PC-PLC (5, 8,  17). To demon- 
strate both cytotoxicity and PC-PLC activation in the same 
cell type, WT and a TNF-R55  deletion mutant lacking the 
death domain were expressed in 70/Z3  cells. As shown in 
Fig.  1,  parental murine pre-B cells 70Z/3  do not respond 
to hTNF,  as these cells do not express TNF-R55  (4). No- 
tably,  triggering  of TNF-R75  by  mTNF  neither  led  to 
PC-PLC  activation nor produced cytotoxic effects on pa- 
rental  70Z/3  cells  (Fig.  1,  C  and  D).  In  contrast,  70Z/3 
transfectants expressing the WT  human  TNF-R55  recep- 
tor responded to  hTNF  with  activation of both  PC-PLC 
and  PLA  2  and  also  resulted  in  cell  death.  The  TNF- 
R55A345 deletion mutant truncated COOH-terminally by 
81  amino acids to destroy the death domain proved defec- 
tive  in  triggering cell  death  (Fig.  1  D),  as  has  been  de- 
scribed for  other  cell  types  (5,  17).  The  TNF-K55A345 
deletion mutant fully retained its ability to signal PLA2 acti- 
vation, but failed to stimulate PC-PLC  (Fig.  1,  B  and  C). 
These  findings support the idea that  PC-PLC  rather  than 
PLA  2 mediates the cytotoxic activity of the  death domain 
of TNF-R55. Along these lines, overexpression of TRADD, 
a  recently  identified  TNF-tk55-associated  protein  that 
contains a death domain itself and that is able to confer cy- 
totoxicity (24),  results in  enhanced  PC-PLC  responses  in 
TNF-treated cells (our own unpublished observations). 
Inhibition of PC-PLC Blocks TNF Cytotoxicity.  To  con- 
firm a role of PC-PLC in TNF cytotoxicity, D609 (18) was 
employed. Two  different TNF-sensitive murine  cell lines, 
L929 and Wehi 164, were preincubated with increasing con- 
centrations of mTNF  in  the presence  of I  btg/ml actino- 
mycin D,  to  sensitize these  cells for TNF  action  (21,  22). 
As shown in Fig. 2, D609 treatment of Wehil64 and L929 
cells resulted in dose-dependent inhibition of TNF-medi- 
ated cytotoxicity. A  close to complete blockade of TNF cy- 
totoxicity was  achieved at 25  btg/ml D609.  mTNF  killed 
Wehi164  cells within 24  h  even in the absence of actino- 
mycin D,  which was  also inhibitable by D609  (Fig. 2  B), 
The inhibitory effect of D609 on TNF-mediated cytotoxic- 
ity was also observed with TNF-R55-transfected 70Z/3 cells 
treated with hTNF  (data not shown).  We have previously 
shown that TNF-induced activation of PC-PLC couples to 
the production of the second messenger ceramide by acti- 
vation of A-SMase (12).  Ceramide in turn has been impli- 
cated as an important mediator of cell death  (25).  In con- 
trast to TNF, C6-ceramide-induced cell death ofWehil64 
cells is not sensitive to D609  (Fig. 3), which rules out non- 
specific protective effects  of D609.  Furthermore,  this  ex- 
periment confirms that  D609  operates upstream  of TNF- 
induced ceramide generation. 
As shown in Fig. 4,  TNF induces transient activation of 
both  PC-PLC  and PLA  2 in Wehi164  cells. TNF-induced 
PC-PLC  activation in Wehi164  cells could be  effectively 
prevented by D609 at concentrations between  12.5  and 50 
b~g/ml (Fig. 4, A  and B), whereas TNF-stimulated activa- 
tion  of PLA  2  remained  completely  unaffected  by  D609 
(Fig. 4  C).  These results confirm that PC-PLC rather than 
PLA  2 plays an essential role in TNF-mediated cytotoxicity. 
D609 Blocks Proinflammatory Effects of TNF In Vivo.  It is 
important to emphasize that the cytotoxic effects of TNF on 
long-term cultured cell lines are not tantamount to the patho- 
physiological effects of TNF in vivo. The activation of PC- 
Figure 5.  D609 inhibits TNF-induced expression of VCAM-1 by lung endothelial cells and leukocyte infiltration of the lungs. Mice were left un- 
treated (A and B), treated with 5 p,g mTNF i.p. (C and D) or 5 la,g  mTNF in combination with three doses of 50 mg/kg D609 (E and F 0, 1, and 4 h 
after mTNF administration). After 8 h, cryostat sections from frozen lung tissue were prepared and analyzed for expression of either VCAM-1 (A, C, and 
E) or Mac-1 (B, D, and F). In each instance, the representative section from one out of four mice (two independent experiments) is shown. Scale bar, 
100 bLM). 
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Figure 6.  D609  protects mice 
from  TNF-,  LPS-,  or  SEB- 
mediated lethal shock. (A)  Fe- 
male BALB/c mice (6--8-wk-old) 
were coinjected with 20 mg GaIN 
and  3  btg  recombinant mTNF 
i.p. Mice were left untreated (0) 
or injected with 50 mg/kg D609 
i.p. at 0, 1, and 4 h (arrows) after 
administration  of mTNF  (O). 
(B) BALB/c Mice were simulta- 
neously  injected with  20  mg 
GaIN  and  100  p,g  SEB, i.p. 
(Toxin  Technology,  Madison, 
WI).  Mice were left untreated 
(0)  or injected with 50  mg/kg 
D609 i.p. at 30 rain, 1 h, and 4 h 
after  SEB  administration  (O). 
(C) BALB/c mice were injected 
with 500 p,g LPS i.p. Mice were 
left  untreated (0)  or  injected 
with 50  ~g/kg D609 i.p. at 30 
rain,  I  h, and 4 h  (arrows)  after 
LPS administration (C)). Statisti- 
cal analyses were performed us- 
ing  the  log  rank test (Kaplan- 
Meyer analysis). 
PLC results in the  generation of DAG, which triggers the 
activation of at least two enzymes, PKC and A-SMase (11, 
12,  26),  and  eventually  the  activation  of the  transcription 
factor NF-•B  (12).  NF-KB  in  turn  has  been  reported  to 
control the expression of several genes encoding cytokines, 
cytokine receptors, adhesion molecules, and acute phase pro- 
teins, and thus is viewed as a key mediator ofproinflamma- 
tory actions (14). This prompted us to investigate whether 
D609 might be effective in blocking the pathophysiological 
effects  of TNF  in  inflammatory  disease  and  septic  shock. 
One prominent proinflammatory effect of TNF includes the 
induction of adhesion molecule expression by endothelial cells 
associated  with  adhesion  of,  and  parenchymal  infiltration 
by, immunocompetent ceils.  It has been shown previously 
that PC-PLC mediates TNF-induced VCAM-1 expression 
by  human  endothelial  cells,  which  can  be  prevented  by 
D609 (27). As illustrated in Fig. 5, mTNF-treated C57BL/6 
mice showed marked induction of VCAM-1 expression by 
lung endothelial  cells  (Fig.  5  C), which was accompanied 
by a  pronounced leukocyte infiltration  (Fig.  5  D).  These 
hallmarks  of the acute respiratory distress syndrome of the 
adult are markedly reduced in mice treated with D609 (Fig. 
5, E and F). 
TNF plays a dominant role in the pathogenesis of septic 
shock  (28).  To  examine  the  effects  of D609  on  TNF- 
induced lethal shock syndrome, BALB/c mice were sensi- 
tized with 20 mg GaIN and subsequently treated with 3  txg 
mTNF.  As shown in Table  1 and Fig. 6 A, three doses of 
50  mg/kg  D609  i.p.  (at  0,  +1,  and  +4  h,  relative  to 
mTNF  challenge)  provided  full  protection  from  TNF- 
mediated lethal toxicity (P <0.005 vs. mTNF).  D609 had 
to be administered repetitively because of its short half-life 
time of 40 rain; the LDs0 of D609 was ~200 mg/kg (data 
not shown).  Control mice treated with either D609  alone 
or GaIN and D609 did not show increased lethality or signs 
of intoxication.  Even  3  mo  after  D609  treatment,  no life 
730  p55 TNFK "Death Domain" Function Table 1.  D609 Protects Mice  fiom TNF-induced Lethal Shock  Table 2.  D609 Protects Mice  fiom SEB-induced Lethal Shock 
D609 
GalN (mg/  TNF (Izg/  BALB/c 
Experiment  mouse)  mouse)  (mg/kg)  (dead/group) 
1"  20  3  -  5/5* 
20  3  3 ￿  502  0/5 
-  -  3  X  50  0/2 
20  3  3 ￿  vehiclell  2/2 
2O  -  3 ￿  50  0/2 
20  3  -  5/5 
20  3  3 ￿  50  1/5 
-  -  3  ￿  50  0/2 
20  3  3 ￿  vehicle  2/2 
20  -  3 ￿  50  0/2 
*Mice received indicated doses of GAIN, TNF, and D609 intraperito- 
neatly in 100 I.tl of sterile PBS. 
*The  final result of the experiment  (survival) was scored after 72 h. 
Surviving mice were monitored for 2 wk; no deaths occurred after 72 h. 
SMice were treated with D609 at 0.5, 1, and 4 h after TNF challenge. 
11100 btl PBS. 
shortening or signs of intoxication were observed (data not 
shown).  Similar results  were  obtained  with  D609,  when 
the  lethal  shock  syndrome  was  induced  by  enterotoxins 
from gram-positive bacteria such as SEB.  SEB functions as 
a  superantigen that cross-links MHC  class II-positive cells 
with T  cells expressing the appropriate V~ segments of the 
TCR  (29). Accordingly, SEB stimulates both macrophages 
and T  lymphocytes, which results in massive cytokine pro- 
duction  (30).  Administration of 100  Izg SEB  and  20  mg 
GaIN produced 80--100% lethality of BALB/c mice within 
72 h  (Fig. 6  B  and Table 2).  Triple injection of 50 mg/kg 
D609 at 30 min,  1 h, and 4 h  after SEB challenge provided 
full protection (P <0.001  vs. SEB; Fig. 6 B, Table 2). Even 
two doses of 50 mg/kg D609  at 1 and 4  h  after SEB chal- 
lenge prevented the lethal shock syndrome.  In contrast,  a 
twofold injection of 25 mg/kg D609,  as well as a single in- 
jection with 100 mg/kg D609, resulted only in incomplete 
(80  and  60%,  respectively)  protection.  In  septic  shock 
models with LPS and SEB,  single cell necroses of hepato- 
cytes are a characteristic feature (31-33).  Livers from SEB- 
challenged  mice  protected with  D609  showed  only mild 
signs of hepatotoxicity. Hepatocytes were not necrotic and 
the  hepatic  architecture  remained  largely unaltered  (data 
not shown). 
Finally, we have examined the effects of D609 on endo- 
toxin-induced lethal shock in the absence of GAIN. Endo- 
toxin (LPS) from gram-negative bacteria represents one major 
causative agent of septic shock, which triggers macrophages 
to  release inflammatory cytokines such  as  TNF  and  IL-1 
(34).  As shown in Fig. 6  C  and Table 3,  mice were sensi- 
tive to a single injection of 500  Izg LPS. A  triple dose with 
50 mg/kg D609 at 30 rain,  1 h, and 4 h  after LPS challenge 
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Experiment 
GaIN  SEB  D609  BALBc 
(mg/  (g,g/  (dead/ 
mouse)  mouse)  (mg/kg)  Treatment  group) 
1"  20  100  -  4/5* 
20  100  3 ￿  50  0.5-1-45  0/5 
-  -  3 ￿  50  0.5-1-4  0/2 
20  100  3 x  vehiclefF  0.5-1-4  2/2 
20  -  3 ￿  50  0.5-1-4  0/2 
2  20  100  -  4/5 
20  100  3 ￿  50  0.5-1-4  0/5 
-  -  3  ￿  50  0.5-1-4  0/2 
20  100  3 X vehicle  0.5-1-4  2/2 
20  -  3 ￿  50  0.5-1-4  0/2 
3  20  100  -  5/5 
20  100  2 ￿  50  1-4  0/5 
-  -  2  X  50  1-4  0/2 
4  20  100  -  4/5 
20  100  2 X 50  1-4  0/5 
-  -  2  X  50  1-4  0/2 
5  20  100  -  5/5 
20  100  2  ￿  25  1-4  1/5 
-  -  2  ￿  25  1-4  0/2 
6  20  100  -  5/5 
20  100  i  ￿  100  1  2/5 
-  -  1  x  100  1  0/2 
*Mice received indicated doses of GalN, SEB, and D609 intraperito- 
neally in 100 I.tl of sterile PBS. 
~:The final result of the experiment  (survival) was scored after 72 h. 
Surviving mice were monitored for 2 wk; no deaths occurred atier 72 h. 
STime (h) after SEB challenge. 
II 100 ILl PBS. 
protects  mice  from  LPS-induced lethal shock  (P  <0.005 
vs. LPS). These observations show that the protective prin- 
ciple  of PC-PLC  inhibition  extends  to  the  LPS-induced 
shock syndrome, where TNF represents but one chief me- 
diator of toxicity. 
PC-PLC: An Endogenous Pathogenicity Factor.  The  pro- 
tective effects of D609 in TNF-, SEB-, or LPS-induced le- 
thal shock may be explained by both inhibition of possible 
direct toxic effects of PC-PLC  and blockade of important 
signaling functions of PC-PLC.  It is important to note that 
PC-PLC is also involved in the signaling pathways of other 
inflammatory cytokines such as IL-1  and IFN-y (for a  re- 
view see reference 13), which synergize with TNF to pro- 
duce a lethal shock syndrome. Interestingly, D609 does not 
inhibit SEB-induced release oflL-1, TNF, or IFN"/in SEB- 
treated mice (our own unpublished observations). This is in 
contrast to  other known  inhibitors of LPS/SEB-mediated 
lethal shock, such as chlorpromazine, adenosine kinase in- Table 3.  D609 Protects Mice  fiom LPS-induced Lethal Shock 
LPS  D609  BALB/c 
Experiment  (txg per mouse)  (mg/kg)  (dead/group) 
1"  500  -  5/5* 
500  3 ￿  50~  0/5 
-  3  ￿  50  O/2 
500  3 ￿  vehiclell  2.2 
2  500  -  5/5 
5OO  3 ￿  5O  O/5 
-  3  x  50  0/2 
500  3 X vehicle  2/2 
*Mice received indicated doses of LPS and D609 intraperitoneally in 
100 jxl of sterile PBS. 
*The  final result of the experiment  (survival) was scored after 72 h. 
Surviving mice were monitored for 2 wk; no deaths occurred after 72 h. 
~Mice were treated with D609 at 0.5, 1, and 4 h after LPS challenge. 
11100 pA PBS. 
hibitor GP-1-515, or tyrphostine, all of which diminish cy- 
tokine production (35-37).  What is the mechanism of the 
pathogenic potential of PC-PLC in vivo? Clues may come 
from bacterial counterparts of eukaryotic PC-PLCs. Bacte- 
rial PC-PLCs  belong to  a  family of membrane-damaging 
toxins  that  are  known  as  virulence  factors.  For  example, 
the ix-toxin of Clostridium  pofringens consists of a PC-PLC 
activity (38).  Interestingly, D609  proved to be an efficient 
inhibitor of any bacterial PC-PLC  investigated (our  own 
unpublished observations). However, it is important to note 
that the substrate, PC, is asymmetrically distributed on eu- 
karyotic membranes in that PC is located predominantly at 
the outer leaflet of plasma membrane  (39).  Thus  PC-PLC 
operating at the outer leaflet may damage the homeostasis 
of the  plasma  membrane  by  excessive  PC  hydrolysis.  In 
contrast,  the  TNF-responsive  PC-PLC  might  not  be  di- 
rectly cytotoxic because it catalyzes only limited PC break- 
down due to low level substrate concentration at the inner 
leaflet. We  therefore  conclude  that  the pathogenic  action 
of PC-PLC  resides in its capacity as a  signaling molecule. 
The  inhibition of PC-PLC  might prove  a  valuable thera- 
peutic  modality  for  inflammatory  diseases,  especially be- 
cause it can block the action of already secreted proinflam- 
matory cytokines. 
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